PubHawk
J Am Acad Dermatol August 2010 PMID 20605255

Efficacy, safety, and tolerability of dutasteride 0.5 mg once daily in male patients with male pattern hair loss: a randomized, double-blind, placebo-controlled, phase III study.

Hee Chul Eun, Oh Sang Kwon, Je Ho Yeon, Hyo Seung Shin, Byung Yoon Kim, Byung In Ro, Han Kyong Cho, Woo Young Sim, Bark Lynn Lew, Won-Soo Lee, Hwa Young Park, Seung Phil Hong, Jae Hong Ji

Full text PDF Download social card

Mentions

8
Peak: 3 in Nov 2024
across 3 sources since Dec 2023

Extended reach

32,948
potential audience

Total likes

490

Video views

31,259

Mentions per month

Dec 2023 – Nov 2024

Where it's discussed

  • X / Twitter3 posts
  • YouTube3 videos
  • News2 articles

AI synopsis

What people are saying

Discussions around the article reveal a generally supportive tone, with many emphasizing the study's positive results, such as mentions of the 153 participants, the double-blind methodology, and the safety profile. The tone and word choices, like 'significant increase' and 'well tolerated,' indicate a moderate level of engagement and recognition of the study’s potential impact in treating hair loss, reflecting both interest and perceived importance.

AgreementModerate agreement

Most discussions support the positive implications of the study, emphasizing the treatment’s efficacy and safety.

InterestHigh interest

Several posts express high interest, highlighting the significance of phase III trials and new options for male pattern hair loss.

EngagementModerate engagement

Posts show some depth, referencing specifics such as the number of participants (153 men) and the study duration, indicating engagement with the research details.

ImpactModerate impact

The discussions suggest the study could influence clinical practices and patient decision-making regarding dutasteride treatment.

Abstract in brief

  • Dutasteride (Avodart) effectively inhibits the conversion of testosterone to dihydrotestosterone, which is linked to male pattern hair loss.
  • A phase III double-blind study with 153 men showed that those taking 0.5 mg of dutasteride experienced a significant increase in hair counts compared to the placebo group.
  • The treatment was well tolerated, with no major difference in side effects between the two groups, although the study was only conducted over a 6-month period.
Read the full abstract

Top posts

Most liked on X and Bluesky
ゆとり｜モテ男になる美容×AGA薄毛ケアで
@kae_extort · X

RT @doctor_neco: まずはプラセボと比較した試験のデータから紹介しましょう 153人の男性をランダムに、デュタステリド内服、プラセボ内服に分けて効果を検証しました 6か月時点で、デュタステリドはプラセボに比べ有意な発毛効果を示しました DOI: 10.1016/…

Nov 27, 2024 · 2 shares · 1,422 followers View post →
ねこ先生@AGA治療エビデンス解説
@doctor_neco · X

RT @doctor_neco: まずはプラセボと比較した試験のデータから紹介しましょう 153人の男性をランダムに、デュタステリド内服、プラセボ内服に分けて効果を検証しました 6か月時点で、デュタステリドはプラセボに比べ有意な発毛効果を示しました DOI: 10.1016/…

Nov 27, 2024 · 2 shares · 128 followers View post →

All mentions

ゆとり｜モテ男になる美容×AGA薄毛ケアで
@kae_extort · X

RT @doctor_neco: まずはプラセボと比較した試験のデータから紹介しましょう 153人の男性をランダムに、デュタステリド内服、プラセボ内服に分けて効果を検証しました 6か月時点で、デュタステリドはプラセボに比べ有意な発毛効果を示しました DOI: 10.1016/…

Nov 27, 2024 · 2 shares · 1,422 followers View post →
ねこ先生@AGA治療エビデンス解説
@doctor_neco · X

RT @doctor_neco: まずはプラセボと比較した試験のデータから紹介しましょう 153人の男性をランダムに、デュタステリド内服、プラセボ内服に分けて効果を検証しました 6か月時点で、デュタステリドはプラセボに比べ有意な発毛効果を示しました DOI: 10.1016/…

Nov 27, 2024 · 2 shares · 128 followers View post →
ねこ先生@AGA治療エビデンス解説
@doctor_neco · X

まずはプラセボと比較した試験のデータから紹介しましょう 153人の男性をランダムに、デュタステリド内服、プラセボ内服に分けて効果を検証しました 6か月時点で、デュタステリドはプラセボに比べ有意な発毛効果を示しました DOI: 10.1016/j.jaad.2009.09.018 https://t.co/gp4vh50HkC

Nov 5, 2024 · 2 shares · 128 followers View post →